|
KMID : 1040620240300020263
|
|
Clinical and Molecular Hepatology
2024 Volume.30 No. 2 p.263 ~ p.265
|
|
|
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
|
|
Hiroyuki Suzuki
Shigeo Shimose
Hideki Iwamoto
Takashi Niizeki
Takumi Kawaguchi
|
|
|
Abstract
|
|
|
|
|
|
|
KEYWORD
|
|
|
Fatty liver, Metabolic syndrome, Immunotherapy, Hepatocellular carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|